1. Home
  2. Live Updates
  3. தேர்வு கண்டறியும் அமைப்பு

தேர்வு கண்டறியும் அமைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேர்வு கண்டறியும் அமைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேர்வு கண்டறியும் அமைப்பு Today - Breaking & Trending Today

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment wi


Font : A-A+
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. 
“Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.” ....

United States , Jared Maxwell , Daisuke Aoki , Bracanalysis Cdx , Scott Gleason , Nicole Lambert , Hu Group Holdings Inc , Department Of Obstetrics , Keio University School Of Medicine , American Society Of Clinical Oncology , Prometheus Labs Inc , Tsrl Inc , Takeda Pharmaceutical Company , Bank Intl , Genetics Inc , Exchange Commission , Supreme Court , Japan Ministry Of Health , Alice Corp , Diagnostic System , Myriad Genetic , Professor Daisuke Aoki , Keio University School , American Society , Clinical Oncology , Choice Diagnostic System ,

Myriad Genetics Receives First Reimbursement Decision for myChoice Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula


Posted January 8th, 2021 for Myriad
SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. 
“Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.” ....

United States , Daisuke Aoki , Bracanalysis Cdx , Nicole Lambert , Hu Group Holdings Inc , Department Of Obstetrics , Keio University School Of Medicine , American Society Of Clinical Oncology , Tsrl Inc , Takeda Pharmaceutical Company , Genetics Inc , Japan Ministry Of Health , Diagnostic System , Myriad Genetic , Professor Daisuke Aoki , Keio University School , American Society , Clinical Oncology , Choice Diagnostic System , Choice Diagnostic , Risk Hereditary Cancer , Myriad Genetics , Breast Cancer , Health Care , Ovarian Cancer , Association For Molecular Pathologyv Myriad Genetics ,

Myriad Receives Reimbursement Decision For MyChoice Diagnostic System


Myriad Receives Reimbursement Decision For MyChoice Diagnostic System
TOKYO (dpa-AFX) - Myriad Genetics, Inc. (MYGN) said it received first reimbursement decision for the myChoice Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula. myChoice was approved by Japan s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication.
Myriad has been collaborating with Takeda Pharma in Japan since 2017 on the development of companion diagnostics. The company has partnered with SRL Inc. to commercialize the myChoice Diagnostic System in Japan.
Copyright RTT News/dpa-AFX
© 2021 AFX News ....

Takeda Pharma , Genetics Inc , Japan Ministry Of Health , Choice Diagnostic System , டாகேடா பார்மா , ஜெநெடிக்ஸ் இன்க் , ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் , தேர்வு கண்டறியும் அமைப்பு ,